VELA Investment Management LLC Reduces Holdings in Bruker Corporation $BRKR

VELA Investment Management LLC reduced its stake in Bruker Corporation (NASDAQ:BRKR) by 22.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 77,459 shares of the medical research company’s stock after selling 23,067 shares during the quarter. VELA Investment Management LLC owned about 0.05% of Bruker worth $4,661,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Pallas Capital Advisors LLC acquired a new position in Bruker during the 2nd quarter valued at approximately $570,746,000. Orbis Allan Gray Ltd acquired a new stake in shares of Bruker during the second quarter worth $192,735,000. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of Bruker during the second quarter valued at $169,899,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Bruker by 2,963.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock valued at $111,488,000 after buying an additional 2,289,269 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after acquiring an additional 1,850,215 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Price Performance

Shares of BRKR stock opened at $58.50 on Monday. Bruker Corporation has a twelve month low of $29.84 and a twelve month high of $65.30. The stock has a market cap of $8.91 billion, a P/E ratio of -83.57, a P/E/G ratio of 1.79 and a beta of 1.26. The stock has a 50 day moving average of $58.76 and a 200 day moving average of $48.73. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.38 by $0.11. The business had revenue of $838.50 million for the quarter, compared to analyst estimates of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, sell-side analysts expect that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Monday, September 21st will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Bruker’s dividend payout ratio is -28.57%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on BRKR shares. UBS Group set a $60.00 target price on Bruker in a research note on Wednesday, June 24th. Zacks Research lowered Bruker from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 2nd. Barclays raised their price objective on Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. JPMorgan Chase & Co. upped their target price on Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a research report on Monday, June 8th. Finally, Wolfe Research initiated coverage on shares of Bruker in a report on Monday, June 1st. They issued a “peer perform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bruker has a consensus rating of “Hold” and a consensus price target of $56.64.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.